BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17620343)

  • 1. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.
    Yoo HH; Lee MW; Kim YC; Yun CH; Kim DH
    Drug Metab Dispos; 2007 Oct; 35(10):1759-65. PubMed ID: 17620343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
    Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
    Draper AJ; Madan A; Parkinson A
    Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
    Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
    Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
    Siu EC; Tyndale RF
    J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo.
    Ueng YF; Chen CC; Chung YT; Liu TY; Chang YP; Lo WS; Murayama N; Yamazaki H; Souček P; Chau GY; Chi CW; Chen RM; Li DT
    Br J Pharmacol; 2011 Jul; 163(6):1250-62. PubMed ID: 21418183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine.
    Le Gal A; Dréano Y; Lucas D; Berthou F
    Toxicol Lett; 2003 Sep; 144(1):77-91. PubMed ID: 12919726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single oral dose pharmacokinetics of decursin, decursinol angelate, and decursinol in rats.
    Li L; Zhang J; Xing C; Kim SH; Lü J
    Planta Med; 2013 Mar; 79(3-4):275-80. PubMed ID: 23364885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 Isoforms in the Metabolism of Decursin and Decursinol Angelate from Korean Angelica.
    Zhang J; Li L; Tang S; Hale TW; Xing C; Jiang C; Lü J
    Am J Chin Med; 2015; 43(6):1211-30. PubMed ID: 26394652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Xenograft Inhibitory Activity and Pharmacokinetics of Decursinol, a Metabolite of Angelica gigas Pyranocoumarins, in Mouse Models.
    Wu W; Tang SN; Zhang Y; Puppala M; Cooper TK; Xing C; Jiang C; Lü J
    Am J Chin Med; 2017; 45(8):1773-1792. PubMed ID: 29121805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical characterization of decursin and their derivatives for drug discovery.
    Mahat B; Chae JW; Baek IH; Song GY; Song JS; Ma JY; Kwon KI
    Drug Dev Ind Pharm; 2013 Oct; 39(10):1523-30. PubMed ID: 23003006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas.
    Lee S; Lee YS; Jung SH; Shin KH; Kim BK; Kang SS
    Arch Pharm Res; 2003 Sep; 26(9):727-30. PubMed ID: 14560921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of human CYP2A6 and rat CYP2B1 in the oxidation of (+)-fenchol by liver microsomes.
    Miyazawa M; Gyoubu K
    Xenobiotica; 2007 Sep; 37(9):943-53. PubMed ID: 17992728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes.
    Endo T; Ban M; Hirata K; Yamamoto A; Hara Y; Momose Y
    Drug Metab Dispos; 2007 Mar; 35(3):476-83. PubMed ID: 17178767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.
    Khojasteh-Bakht SC; Koenigs LL; Peter RM; Trager WF; Nelson SD
    Drug Metab Dispos; 1998 Jul; 26(7):701-4. PubMed ID: 9660853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
    Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
    Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
    Taavitsainen P; Juvonen R; Pelkonen O
    Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro metabolism of pyranocoumarin isomers decursin and decursinol angelate by liver microsomes from man and rodents.
    Li L; Zhang J; Xing C; Kim SH; Jiang C; Lü J
    Planta Med; 2013 Nov; 79(16):1536-44. PubMed ID: 24026903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porcine CYP2A polymorphisms and activity.
    Skaanild MT; Friis C
    Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):115-21. PubMed ID: 15998359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.